Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
The presence of A beta(pE3) (N-terminal truncated A beta starting with pyroglutamate) in Alzheimer's disease (AD) has received considerable attention since the discovery that this peptide represents a dominant fraction of A beta peptides in senile plaques of AD brains. This was later confirmed...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2010
|
Subjects: | |
Online Access: | http://hdl.handle.net/11245/1.310691 |
id |
ftunivamstpubl:oai:uvapub:310691 |
---|---|
record_format |
openpolar |
spelling |
ftunivamstpubl:oai:uvapub:310691 2023-05-15T15:11:42+02:00 Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases O. Wirths T. Bethge A. Marcello A. Harmeier S. Jawhar P.J. Lucassen G. Multhaup D.L. Brody T. Esparza M. Ingelsson H. Kalimo L. Lannfelt T.A. Bayer 2010 http://hdl.handle.net/11245/1.310691 en eng 10.1007/s00702-009-0314-x It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content licence (like Creative Commons). Journal of Neural Transmission (03009564) vol.117 (2010) nr.1 p.85-96 article 2010 ftunivamstpubl 2015-11-19T11:16:00Z The presence of A beta(pE3) (N-terminal truncated A beta starting with pyroglutamate) in Alzheimer's disease (AD) has received considerable attention since the discovery that this peptide represents a dominant fraction of A beta peptides in senile plaques of AD brains. This was later confirmed by other reports investigating AD and Down's syndrome postmortem brain tissue. Importantly, A beta(pE3) has a higher aggregation propensity, and stability, and shows an increased toxicity compared to full-length A beta. We have recently shown that intraneuronal accumulation of A beta(pE3) peptides induces a severe neuron loss and an associated neurological phenotype in the TBA2 mouse model for AD. Given the increasing interest in A beta(pE3), we have generated two novel monoclonal antibodies which were characterized as highly specific for A beta(pE3) peptides and herein used to analyze plaque deposition in APP/PS1KI mice, an AD model with severe neuron loss and learning deficits. This was compared with the plaque pattern present in brain tissue from sporadic and familial AD cases. Abundant plaques positive for A beta(pE3) were present in patients with sporadic AD and familial AD including those carrying mutations in APP (arctic and Swedish) and PS1. Interestingly, in APP/PS1KI mice we observed a continuous increase in A beta(pE3) plaque load with increasing age, while the density for A beta(1-x) plaques declined with aging. We therefore assume that, in particular, the peptides starting with position 1 of A beta are N-truncated as disease progresses, and that, A beta(pE3) positive plaques are resistant to age-dependent degradation likely due to their high stability and propensity to aggregate. Article in Journal/Newspaper Arctic Universiteit van Amsterdam: Digital Academic Repository (UvA DARE) Arctic |
institution |
Open Polar |
collection |
Universiteit van Amsterdam: Digital Academic Repository (UvA DARE) |
op_collection_id |
ftunivamstpubl |
language |
English |
description |
The presence of A beta(pE3) (N-terminal truncated A beta starting with pyroglutamate) in Alzheimer's disease (AD) has received considerable attention since the discovery that this peptide represents a dominant fraction of A beta peptides in senile plaques of AD brains. This was later confirmed by other reports investigating AD and Down's syndrome postmortem brain tissue. Importantly, A beta(pE3) has a higher aggregation propensity, and stability, and shows an increased toxicity compared to full-length A beta. We have recently shown that intraneuronal accumulation of A beta(pE3) peptides induces a severe neuron loss and an associated neurological phenotype in the TBA2 mouse model for AD. Given the increasing interest in A beta(pE3), we have generated two novel monoclonal antibodies which were characterized as highly specific for A beta(pE3) peptides and herein used to analyze plaque deposition in APP/PS1KI mice, an AD model with severe neuron loss and learning deficits. This was compared with the plaque pattern present in brain tissue from sporadic and familial AD cases. Abundant plaques positive for A beta(pE3) were present in patients with sporadic AD and familial AD including those carrying mutations in APP (arctic and Swedish) and PS1. Interestingly, in APP/PS1KI mice we observed a continuous increase in A beta(pE3) plaque load with increasing age, while the density for A beta(1-x) plaques declined with aging. We therefore assume that, in particular, the peptides starting with position 1 of A beta are N-truncated as disease progresses, and that, A beta(pE3) positive plaques are resistant to age-dependent degradation likely due to their high stability and propensity to aggregate. |
format |
Article in Journal/Newspaper |
author |
O. Wirths T. Bethge A. Marcello A. Harmeier S. Jawhar P.J. Lucassen G. Multhaup D.L. Brody T. Esparza M. Ingelsson H. Kalimo L. Lannfelt T.A. Bayer |
spellingShingle |
O. Wirths T. Bethge A. Marcello A. Harmeier S. Jawhar P.J. Lucassen G. Multhaup D.L. Brody T. Esparza M. Ingelsson H. Kalimo L. Lannfelt T.A. Bayer Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases |
author_facet |
O. Wirths T. Bethge A. Marcello A. Harmeier S. Jawhar P.J. Lucassen G. Multhaup D.L. Brody T. Esparza M. Ingelsson H. Kalimo L. Lannfelt T.A. Bayer |
author_sort |
O. Wirths |
title |
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases |
title_short |
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases |
title_full |
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases |
title_fullStr |
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases |
title_full_unstemmed |
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases |
title_sort |
pyroglutamate abeta pathology in app/ps1ki mice, sporadic and familial alzheimer’s disease cases |
publishDate |
2010 |
url |
http://hdl.handle.net/11245/1.310691 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Journal of Neural Transmission (03009564) vol.117 (2010) nr.1 p.85-96 |
op_relation |
10.1007/s00702-009-0314-x |
op_rights |
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content licence (like Creative Commons). |
_version_ |
1766342519058071552 |